Jonathan Hahn - Kamada Director
| KMDA Stock | ILA 1,986 54.00 2.80% |
Director
Mr. Jonathan Hahn is Director of the company. He has served on our board of directors since March 2010. Mr. Hahn is currently the President and a director of Tuteur. Previously, Mr. Hahn held a business development position in Forest Laboratories, Inc., based in New York since 2010.
| Age | 32 |
| Tenure | 14 years |
| Professional Marks | MBA |
| Phone | (972) 8 9406472 |
| Web | www.kamada.com |
Kamada Management Efficiency
Kamada's management efficiency ratios could be used to measure how well Kamada manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Avi Slonim | Bonus Biogroup | 38 | |
| Joshua Shemer | Compugen | 63 | |
| Sanford Zweifach | Compugen | 60 | |
| Rachel Ari | Bonus Biogroup | 55 | |
| Ruth Arnon | Compugen | 86 | |
| Yehuda Reznik | Bonus Biogroup | 68 | |
| Batia Avital | Bonus Biogroup | 54 | |
| Michal Preminger | Compugen | N/A | |
| Arie Ovadia | Compugen | 67 | |
| Eran Perry | Compugen | N/A | |
| Gil Shapira | Bonus Biogroup | 56 | |
| Yair Aharonowitz | Compugen | 73 | |
| Kinneret Savitsky | Compugen | 50 | |
| JeanPierre Bizzari | Compugen | 64 | |
| Dov Hershberg | Compugen | 74 | |
| Gilead Halevy | Compugen | 51 | |
| Daniel BenLulu | Bonus Biogroup | 54 | |
Management Performance
| Return On Equity | -0.058 | |||
| Return On Asset | -0.0023 |
Kamada Leadership Team
Elected by the shareholders, the Kamada's board of directors comprises two types of representatives: Kamada inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kamada. The board's role is to monitor Kamada's management team and ensure that shareholders' interests are well served. Kamada's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kamada's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pnina Strauss, Vice President - Inhalation programs & IP | ||
| Itzhak Krinsky, Director | ||
| Lilach Topilsky, Chairman of the Board | ||
| Ari Shamiss, Director | ||
| Barak Bashari, Vice President - Operations | ||
| Eran Schenker, Vice President - Medical Director | ||
| Tuvia Shoham, Independent Director | ||
| Eran Nir, Chief Officer | ||
| Hanni Neheman, VP Sales | ||
| Michal Stein, Vice President and Medical Director for Immunology | ||
| Ariella Raban, VP HR | ||
| Shani Dotan, Vice President of Human Resources | ||
| Liliana Bar, VP of RandD | ||
| Yael Brenner, Vice President - Quality | ||
| Abraham Havron, Independent Director | ||
| Asaf Frumerman, Director | ||
| Ruth Wolfson, Senior Vice President - Scientific Affairs | ||
| Shmuel Rubinstein, Director | ||
| Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary Diseases | ||
| Jon Knight, VP Operations | ||
| Michael Berelowitz, Director | ||
| David Tsur, Co-Founder and Deputy Executive Chairman | ||
| Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D | ||
| Leon Recanati, Chairman of the Board | ||
| Gil Efron, CFO, Principal Accounting Officer and Deputy CEO | ||
| Jonathan Hahn, Director | ||
| Eran Schenkar, Vice President - Medical Director | ||
| Gwen Melincoff, Director | ||
| Chaime Orlev, Chief Financial Officer | ||
| Michal Ayalon, Vice President - Research & Development | ||
| Yifat Esq, Gen Legal | ||
| Amir London, Chief Executive Officer | ||
| Estery GilozRan, Independent Director | ||
| Reuven Behar, Director | ||
| Eitan Kyiet, Vice President - Business Development | ||
| Ziv Kop, Director |
Kamada Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kamada a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.058 | |||
| Return On Asset | -0.0023 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 636.38 M | |||
| Shares Outstanding | 44.8 M | |||
| Shares Owned By Insiders | 18.50 % | |||
| Shares Owned By Institutions | 32.04 % | |||
| Price To Book | 1.13 X | |||
| Price To Sales | 5.37 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kamada. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Kamada Stock refer to our How to Trade Kamada Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Kamada Stock analysis
When running Kamada's price analysis, check to measure Kamada's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kamada is operating at the current time. Most of Kamada's value examination focuses on studying past and present price action to predict the probability of Kamada's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kamada's price. Additionally, you may evaluate how the addition of Kamada to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |